Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China

INTRODUCTION: To investigate the effect of dose maintenance, reduction, or discontinuation of the etanercept biosimilar Yisaipu (YSP) on early axial spondyloarthritis (axSpA) patients in remission with YSP 50 mg once weekly (QW). MATERIAL AND METHODS: Patients were enrolled in three groups: full dos...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Arch Med Sci
Autors principals: Li, Kun-Peng, Jin, Jing-Yu, Yang, Jin-Shui, Li, Yan, Zhao, Wei, Luo, Gui, Zhu, Jian, Zhang, Jiang-Lin, Huang, Feng
Format: Artigo
Idioma:Inglês
Publicat: Termedia Publishing House 2018
Matèries:
Clinical Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6524190/
https://ncbi.nlm.nih.gov/pubmed/31110537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/aoms.2018.76141
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars